ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases with 2.2 Software and Integrated Maestro Brain Model

ClearPoint Neuro has made significant progress with the FDA clearance and initial human trials of the ClearPoint 2.2 Software, now equipped with Maestro Brain Modeling integration. This integration enhances the ClearPoint system's capabilities for precise navigation in brain and spine procedures.

The Maestro Brain Model, seamlessly integrated into the ClearPoint 2.2 navigation software, facilitates rapid segmentation of cortical brain structures. This assists in identifying targets and safety zones for various procedures like cell and gene therapy delivery, laser ablation, biopsy, and deep brain stimulation. In MRI-guided neuro interventions, where swift, accurate, and reproducible segmentation is crucial, the ClearPoint system aims to excel.

The manuscript detailing the methodology behind the shape-constrained deformable brain segmentation, which powers Maestro, outlines the validation process for FDA clearance. It also compares results with manual expert segmentation and FreeSurfer, an open-source segmentation software. The analysis demonstrates superior performance in accuracy and reproducibility compared to both manual segmentation and FreeSurfer.

The shape-constrained methodology ensures precise and consistent segmentation. Additionally, the inherent point-based correspondence enhances target identification, particularly advantageous for MRI-guided neuro interventions. This advancement signifies a significant leap in enabling more precise and effective neurosurgical procedures, potentially leading to improved patient outcomes and advancements in neurology.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress